Department of Medicine, Columbia University, New York, New York, USA.
Gastrointest Endosc. 2012 Aug;76(2):293-300. doi: 10.1016/j.gie.2012.04.445.
EUS-guided FNA is one of the few techniques that can obtain cells and tissue from the liver and pancreas. However, the technique remains vulnerable to poor specimen quality and sampling error.
To evaluate the ability of a high-resolution microendoscope (HRME) to visualize the cellular and architectural features of normal and malignant liver and pancreatic tissue ex vivo, to assess the ability of endosonographers to identify normal and neoplastic tissue by using HRME images, and to demonstrate preliminary technical feasibility of in vivo HRME imaging via EUS fine-needle puncture (FNP).
Ex vivo pilot feasibility study in human tissue; in vivo swine model.
Two academic medical centers.
Co-registered HRME images and biopsies were obtained from surgically resected hepatic and pancreatic tissues from 44 patients.
Images were divided into training (12 images) and test (80 images) sets containing a range of normal and pathologic conditions for each organ. After viewing the training sets, 9 endosonographers attempted to distinguish malignant tissue from normal or benign lesions in the test sets, each of which contained 40 unique images with individual diagnoses from pathology.
Image acquisition feasibility, ex vivo and in vivo. Ability of endosonographers to recognize features of normal/benign or malignant tissue from the liver and pancreas.
Overall, the 9 endosonographers achieved median accuracy figures of 85% in the liver and 90% in the pancreas. The endosonographers with prior experience in reading HRME images achieved accuracy rates between 90% and 95%. Technical feasibility of HRME imaging through a 19-gauge EUS-FNP needle was demonstrated in an in vivo swine model.
Ex vivo study.
High-resolution microendoscopy allows real-time imaging of cellular-level morphology and tissue architecture in the liver and pancreas. The technique appears to have a short learning curve, after which endosonographers achieved high accuracy rates in distinguishing malignant tissue from normal and benign pathology in both organs. Translating this imaging platform to the in vivo setting appears technically feasible.
EUS 引导下的 FNA 是为数不多的能够从肝脏和胰腺获取细胞和组织的技术之一。然而,该技术仍然容易受到标本质量差和采样误差的影响。
评估高分辨率微内镜 (HRME) 可视化正常和恶性肝、胰腺组织细胞和结构特征的能力,评估内镜医师通过 HRME 图像识别正常和肿瘤组织的能力,并通过 EUS 细针穿刺 (FNP) 证明体内 HRME 成像的初步技术可行性。
在人体组织中进行的体外初步可行性研究;体内猪模型。
两个学术医疗中心。
从手术切除的肝和胰腺组织中获得了共配准的 HRME 图像和活检标本,来自 44 名患者。
将图像分为训练集(12 张图像)和测试集(80 张图像),每个器官的图像均包含一系列正常和病理条件。在查看完训练集后,9 名内镜医师尝试在测试集中区分恶性组织与正常或良性病变,每个测试集包含 40 张来自病理的独特图像和各自的诊断。
图像采集的可行性,体外和体内。内镜医师从肝脏和胰腺识别正常/良性或恶性组织特征的能力。
总体而言,9 名内镜医师在肝脏中的准确率中位数为 85%,在胰腺中的准确率中位数为 90%。有 HRME 图像阅读经验的内镜医师的准确率在 90%至 95%之间。在体内猪模型中,通过 19 号针 EUS-FNP 成功演示了 HRME 成像的技术可行性。
体外研究。
高分辨率微内镜可实时成像肝脏和胰腺的细胞水平形态和组织结构。该技术似乎具有较短的学习曲线,之后内镜医师在两个器官中都能达到很高的准确率,从正常和良性病理学中区分恶性组织。将该成像平台转化为体内环境在技术上似乎是可行的。